Annals of Clinical Oncology and Cancer Research | Volume 1, Issue 1 | Review Article | Open Access DOI
Bambara HA*
Bambara HA1,2*, Zerbo NJ1, M’PO MC1, Youbi ZA3, Kietega GGA3, Minoungou AAN3, Mosse BAW3, Sieba I3, Sigue KONE M3, Kadyogo M4, Zongo N5,2, Ouedraogo AS6,2, Ouedraogo S7,8, Ouattara A9,2, ZIDA M5,2, Ouedraogo B10,2, Sereme M4,2, Ouedraogo CM9,2, Sanou A11,2
1Department of Clinical Hematology Oncology, University Teaching Hospital BOGODOGO in Ouagadougou, BURKINA FASO
2UFR/ SDS, University JOSEPH KI-ZERBO in Ouagadougou, BURKINA FASO
3Radiotherapy Department of the University Teaching Hospital BOGODOGO in Ouagadougou, BURKINA FASO
4ENT department of the University Teaching Hospital BOGODOGO in Ouagadougou, BURKINA FASO
5Department of General and Digestive Surgery of the University Teaching Hospital YALGADO OUEDRAOGO in Ouagadougou, BURKINA FASO
6Pathology and cytopathology Department of the University Teaching Hospital BOGODOGO in Ouagadougou, BURKINA FASO
7Department of General and Digestive Surgery of the Regional University Teaching Hospital OUAHIGOUYA in OUAHIGOUYA, BURKINA FASO
8UFR/SDS, University of OUAHIGOUYA in OUAHIGOUYA, BURKINA FASO
9Gynecology-Obstetrics and Reproductive Health Department of University Teaching Hospital BOGODOGO in Ouagadougou, BURKINA FASO
10ENT Department of the University Teaching Hospital TENGANDGO in Ouagadougou, BURKINA FASO
11Department of General and Digestive Surgery of the University Teaching Hospital TENGANDGO in Ouagadougou, BURKINA FASO
*Correspondence to: Bambara HA
Fulltext PDFIntroduction: Cancer was the second leading cause of death in hospitals after cardiovascular disease in Burkina Faso in 2020. Radiotherapy is involved in the treatment of 60 % of cancers. The radiotherapy center inaugurated in April 2021 allowed to irradiate cancer in Ouagadougou for the first time. Thus, it was possible to perform concurrent chemoradiotherapy (CCRT). The aim of our study was to describe the epidemiological, diagnostic and therapeutic profiles of cancer patients treated with CCRT in Ouagadougou.
Materials and methods: Descriptive cross-sectional study with retrospective collection from May 1, 2021 to April 30, 2022 from the medical records of patients who have benefited from a CCRT. Included in the study was any patient with a confirmed cancer diagnosis whose medical record was presented in a multidisciplinary meeting (MDM) with validation of a neoadjuvant or exclusive CCRT. Chemotherapy was performed in the clinical hematology oncology department and radiotherapy in the radiotherapy center of University Teaching Hospital Bogodogo.
Results: We included 41 patients. The mean age was 54.85 years [35 to 80 years]. Women accounted for 90.2% of cases. Cervical cancers accounted for 87.8% of cases, followed by ENT cancers with 7.3%. Squamous cell carcinoma was the most common histological type. External radiotherapy was used with total doses ranging from 50 to 70 Gy. Chemotherapies were cisplatin (40 mg/m2) or carboplatin (AUC2).
Conclusion: CCRT has improved the treatment of cancer patients who previously only received chemotherapy and/or surgery when medical evacuation out of the country was not possible.
Concurrent chemoradiotherapy; Cancers; Ouagadougou
Bambara HA, Zerbo NJ, M’PO MC, Youbi ZA, Kietega GGA, Minoungou AAN, et al.Epidemiological, Diagnostic and Therapeutic Profiles of Patients Treated with Concurrent Chemoradiotherapy (Ccrt) In Ouagadougou (Burkina Faso).Anna Clin Onc Can Res.2023;1(1):1-9.